We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01494922
First Posted: December 19, 2011
Last Update Posted: November 20, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
December 15, 2011
December 19, 2011
November 20, 2014
December 2011
September 2013   (Final data collection date for primary outcome measure)
Assess the safety of EXC 001 in subjects undergoing elective revision of scars from prior surgery [ Time Frame: Week 24 ]
Assess the safety of EXC 001 in subjects undergoing elective revision of scars from prior surgery [ Time Frame: 6 months ]
Safety will be assessed by number of participants with adverse events.
Complete list of historical versions of study NCT01494922 on ClinicalTrials.gov Archive Site
  • Physician Scar Assessment Scale [ Time Frame: Wk 24 ]
  • Subject Scar Assessment Scale [ Time Frame: Wk 24 ]
  • Physician Reported Scar Severity Scale (Photonumeric Guide) [ Time Frame: Wk 24 ]
  • Subject Reported Scar Severity Scale (Photonumeric Guide) [ Time Frame: Wk 24 ]
Assess the efficacy of EXC 001 in subjects undergoing elective revision of scars from prior surgery [ Time Frame: 6 months ]
Physician and subject scar assessment
Not Provided
Not Provided
 
Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001
A Phase 2, Open-label Study to Provide Revision of Scars Resulting From Surgery in Prior Studies of EXC 001 (Currently Called PF-06473871)
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Reduction in Severity of Skin Scarring
Drug: EXC 001 (currently called PF-06473871)
Single dose administered by injection at four different times
Experimental: Open Label
Intervention: Drug: EXC 001 (currently called PF-06473871)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
September 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy adults who have participated in previous studies of EXC 001.
  • Healthy adults who have chosen to have their scars revised.

Exclusion Criteria:

  • Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or breast feeding.
  • Participation in another clinical trial within 30 days prior to the start of the study.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01494922
EXC 001-206
B5301003
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP